Investor Presentaiton slide image

Investor Presentaiton

Biotech & Infotech 88 00 +85 The scale of the global medical research pipeline has grown to 20,109 by January 2022, up 8.2% from 12 months earlier, according to Informa Pharma Intelligence. The number of R&D companies in China by January 2022 has increased by 43%, bringing its global share from 9% to 12%. Ranked second in terms of new medicine development, China (20.8%) has been upgrading and innovating its biotechnology industry. One example is the new generation of biotherapy featuring gene and cell engineering that provides a potential solution for more precise tumour treatment. A combination of biotech and infotech is bringing more value to the life science sector. Taking "healthcare+Al" as an example, Al can cut the time needed for new drug development and even replace part of a doctor's work. In 2021, research indicated that Al technology could potentially shorten the drug development period to 18 months, and reduce costs by 90% compared to traditional drug development methods. -5,000 Global research pipeline, by Jan 2022 China Life Sciences - 2022 Number (LHS) Growth rate (RHS) 25,000 25% 20,000 20% 15,000 15% 10,000 5,000 பளி 10% 5% 0% 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 Source: Savills Research using Informa Pharmaprojects data -5%
View entire presentation